公司資料
Nutriband 股價、新聞與催化劑
- 股票代碼:
- NTRB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
7.36 USD (-2.13%)
收盤價
最後更新: 2026年10月1日
43.2M USD
市值
股價為何變動
最新監測到的公司動態為「Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders」。相應的收盤價反應尚未產生。
公司概覽
Transdermal Pharmaceutical Company
Nutriband develops transdermal products and provides contract manufacturing services. Its strategy combines near-term manufacturing revenue with proprietary abuse-deterrent patch technology.
AVERSA Abuse-Deterrent Platform
AVERSA incorporates aversive agents into transdermal systems to discourage chewing, extraction, or other misuse. The platform is designed for potent drugs that benefit from continuous delivery but carry abuse risk.
AVERSA Fentanyl
The lead proprietary program applies AVERSA technology to a fentanyl patch. Nutriband is developing the product through the 505(b)(2) pathway with the goal of retaining analgesic delivery while adding abuse deterrence.
Contract Manufacturing Operations
Through Pocono Pharmaceutical, the company develops and manufactures topical and transdermal products for third parties. Services include formulation, coating, converting, packaging, and production of consumer and pharmaceutical patches.
Partner-Supported Development
Nutriband works with external manufacturers, development specialists, and regulatory advisers, including Kindeva for AVERSA Fentanyl. This model gives the company access to commercial-scale transdermal expertise without building every capability internally.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。